Key Laboratory of Medical Molecular Virology of MOE/MOH, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Key Laboratory of Medical Molecular Virology of MOE/MOH, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Stem Cell Reports. 2021 Mar 9;16(3):398-411. doi: 10.1016/j.stemcr.2020.12.010.
While the COVID-19 pandemic caused by SARS-CoV-2 is continuing, it may become worse in the coming winter months with a high potential for the emergence and spread of escape variants of SARS-CoV-2. SARS-related CoVs (SARSr-CoVs) from bats may also cause outbreaks of emerging coronavirus diseases in the future. These predictions call for the development of broad-spectrum anti-coronavirus vaccines and therapeutics to combat the current COVID-19 pandemic and future emerging coronavirus disease epidemics. In this review, we describe advances and challenges in the development of broad-spectrum vaccines and neutralizing antibodies against lineage B betacoronaviruses (β-CoV-Bs), including SARS-CoV-2, SARS-CoV, and SARSr-CoVs, as well as peptide-based pan-CoV fusion inhibitors and their potential in the prevention and treatment of COVID-19 and other human coronavirus infections.
虽然由 SARS-CoV-2 引起的 COVID-19 大流行仍在继续，但随着 SARS-CoV-2 逃逸变异株的出现和传播的可能性增加，未来冬季情况可能会更糟。未来蝙蝠来源的 SARS 相关冠状病毒（SARSr-CoV）也可能引发新的冠状病毒疾病爆发。这些预测呼吁开发广谱抗冠状病毒疫苗和疗法，以应对当前的 COVID-19 大流行和未来新出现的冠状病毒病流行。在这篇综述中，我们描述了针对谱系 B β冠状病毒（β-CoV-Bs），包括 SARS-CoV-2、SARS-CoV 和 SARSr-CoV，以及基于肽的泛冠状病毒融合抑制剂的广谱疫苗和中和抗体的研发进展和挑战，以及它们在 COVID-19 和其他人类冠状病毒感染的预防和治疗中的潜在应用。
